Wantai Biotech announced on December 25 that the human immunodeficiency virus antibody oral mucosal exudate test kit independently developed by the company has obtained the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration. Furthermore, the clinical trial application for the “recombinant trivalent rotavirus subunit vaccine” declared by Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary, has been accepted by the State Drug Administration.

Wantai Biotech announced on December 25 that the human immunodeficiency virus antibody oral mucosal exudate test kit independently developed by the company has obtained the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration. Furthermore, the clinical trial application for the “recombinant trivalent rotavirus subunit vaccine” declared by Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary, has been accepted by the State Drug Administration.